Application of KP-1 to preparation of medicine for treating chronic lung diseases

Abstract

The invention relates to the field of medicine, in particular to an application of KP-1 polypeptide to preparation of a medicine for treating chronic lung diseases. It is found that a micromolecule polypeptide (KP-1) has no obvious toxic or side effect in mouse animal experiments, has a very good inhibition effect on bleomycin-induced pulmonary fibrosis, and can significantly reduce mouse lung interstitial collagen deposition, significantly reduce I-type collagen and fibronectin, and significantly down-regulate key factor expression of a TGF-beta signal channel, so that the KP-1 polypeptide is expected to be used for treating and / or preventing pulmonary fibrosis.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the use of KP-1 (polypeptide) in the preparation of medicines for treating chronic lung diseases. Background technique [0002] Chronic lung disease, formerly known as bronchopulmonary dysplasia, is a group of lung disorders of multiple etiologies. Clinically common chronic lung diseases mainly include recurrent respiratory tract infection, allergic rhinitis, chronic cough, bronchial asthma, chronic bronchitis, pulmonary interstitial fibrosis and other common clinical diseases. Pulmonary fibrosis, as a chronic interstitial lung disease, is the final outcome of various chronic lung diseases. The pathological features of pulmonary fibrosis are mainly inflammatory injury of alveolar epithelial cells, excessive proliferation of fibroblasts, abnormal deposition of extracellular matrix (ECM), abnormal repair and remodeling of lung tissue, which lead to progressive decline of lung function and ...

AI Technical Summary

Problems solved by technology

[0004] However, the pathogenesis of pulmonary fibrosis is not clear, it involves the interaction of multiple factors and multiple signaling pathways, abnormal expression of cytokines, damage and repair of epithelial cells, increase of new blood vessels, abnormal expression of matrix metalloproteinases or oxidative stress and other factors have a certain correlation

At present, there is still no breakthrough in treatment. Delaying the progression of pulmonary fibrosis and reducing the incidence of pulmonary interstitial fibrosis are a huge challenge and a major demand for the prevention and treatment of respiratory diseases.

Images